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Background: Studies have shown that group Therapeutic Patient Education (TPE) may empower patients with type 2
diabetes to better manage their disease. The mechanism of these interventions is not fully understood. A reduction in
resistance to treatment may explain the mechanism by which TPE empowers participants to improve self-management.
The Objective of this study was to examine the effectiveness of diabetes groups in reducing resistance to treatment and
the association between reduced resistance and better management of the disease.
Methods: In a program evaluation study, we administered validated questionnaires to measure resistance to treatment
(RTQ) in 3 time periods: before the intervention (T1), immediately after the intervention (T2) and six months later (T3).
Clinical measures (HbA1C, blood pressure, HDL, LDL and total cholesterol, Triglycerides and BMI) were retrieved from
Maccabi Healthcare Services computerized systems, for T1;T2 and a year post intervention (T3). Linear mixed models
were used adjusting for age, gender, social support and family status.
Results: 157; 156 and 106 TPE participants completed the RTQ in T1; T2 and T3 respectively. HbA1C and systolic and
diastolic blood pressure were significantly reduced in the group which achieved a reduction in three out of the five
RTQ components. For the other clinical measurements no significant changes were observed.
Conclusion: Our findings suggest that reducing resistance to treatment, through an educational program for patients
with diabetes, is associated with a better disease control. Identifying patients with higher resistance to treatment, and
including components that reduce resistance in patient education programs, have the potential to increase the
effectiveness of these programs.
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It is well recognized that adoption of self-management
skills by patients with diabetes is necessary to enable
them to manage their illness [1,2]. The British National
Institute for Clinical Excellence (NICE), have suggested
that the delivery of a structured self-management educa-
tion program for people with diabetes, is a cornerstone
of the management of this chronic condition [3,4]. This
principle is now accepted as being part of the care
delivered to people with diabetes.* Correspondence: liora.v@meuhedet.co.il
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stated.Diabetes is an extremely expensive disease for health
systems. The complications, which are mainly due to
treatment failures, are caused by poor self management
of the disease, rather than by poor organizational re-
source investments. For patients to be able to manage
their disease in a reasonable manner, they need to be
empowered in several dimensions: physically (access),
cognitively (skills) and emotionally (self-efficacy, health
beliefs, readiness for change). Any intervention designed
to improve patient adherence to treatment through self
empowerment, needs to address all of these aspects of
care. Furthermore, participation in an empowerment-
based diabetes self-management support intervention
may have a positive and enduring effect on self-care
behaviors and on metabolic measurements [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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instrument to measure the degree to which patients are
able to accept and cope with different aspect of diabetes
management, including: psychological acceptance, health
care team acceptance, emotional acceptance and overall
acceptance of the diagnosis and its everyday implications.
Additionally, resistance to treatment has been found to be
associated with self-efficacy and readiness to change, and
is therefore a reasonable surrogate for the measurement
of patient empowerment.
Many of the interventions relating to patient behavior,
are conducted within a theoretical framework, such as the
Health belief Model [6] or the Trans Theoretical Model
(TTM) [7-9]. However, when developing an intervention
within constrained resources, it is important to develop
interventions that are not only based on behavioral
models, but that are based on changing patient attitudes,
beliefs and behavior in a measurable manner. Resistance
to treatment as measured by the RTQ can be extremely
useful in this, and can serve as a model for the design of
interventions such as diabetes education groups. Ad-
ditionally, it can serve as a tool for a better recruitment of
targeted participants (individuals that will most likely to
gain from these kind of interventions) and as an eva-
luation tool (to adequately measure the improvement the
group achieved).
Although Therapeutic Patient Education (TPE), for
people with diabetes can be undertaken on an individual
level, by a healthcare provider such as a nurse [10], die-
tician or a physician, by peer groups [11] or electronic re-
mote learning [12], NICE has recommended that diabetes
education should be provided by an appropriately quali-
fied multidisciplinary teams to groups of people with the
disease. Over time, the emphasis in these educational
programs has shifted from a didactic approach to patient
empowerment approaches [10] and it is clear now that
programs incorporating behavioral and psychosocial
strategies with or without ethnic and cultural adaptation
have demonstrated improved outcomes [11-13]. It was
suggested by previous studies, that patients with type 2
diabetes who have participated in TPE programs based on
self-management strategies improved their diabetes con-
trol: fasting blood glucose and glycosylated hemoglobin
(HbA1C) and their knowledge about the disease in the
short (four to six months) and longer-term (12 to 14
months), whilst also reduced the need for diabetes medi-
cation. There is also some evidence that group-based edu-
cation programs may lead to reduced blood pressure and
body weight, and to the increase of self-empowerment,
quality of life, self-management skills and treatment satis-
faction. However, only a small number of studies eva-
luated those outcomes [11].
Maccabi Healthcare Services (MHS) is the second lar-
gest Health Maintenance Organization (HMO) in Israel,providing primary care to 1.9 million residents nation-
wide through five administrative and geographical re-
gions. Physicians are employed in independent practices,
and members have free choice in regard to their own
care-givers. Among MHS beneficiaries, 104,000 are pa-
tients with diabetes and the disease has become one of
the major chronic diseases with a professional and
economic burden.
Based on the assumption that patient empowerment
groups have the potential to improve diabetes self-
management MHS, for many years, encourages diabetic
patients to participate in these TPEs. To date almost 8,000
Patients have participated in these groups, but other than
an evaluation of patient satisfaction, no examination of
the clinical impact was performed.
The Objective of this study was to examine the effec-
tiveness of diabetes groups in reducing resistance to
treatment and the association between reduced resis-
tance and better management of the disease.
Methods
The intervention
Throughout the country we offer structured group inter-
ventions with a very modest co-payment, to empower
patients by providing knowledge, tools and support. The
empowerment model is based on the assumption that to
improve their health, people must bring about changes
not only in their personal behavior but also in their
social situations and in the environment that influences
their lives. This empowerment model has evolved out of
the realization that patients cannot be forced to follow a
lifestyle dictated by others [1].
These intervention groups are run by a specially edu-
cated team consisting of a diabetes nurse, a dietician and a
social worker trained in psychosocial counseling. The
intervention comprises of eight meetings over a period of
two months and spouses are invited to participate. Subjects
on the agenda are: resistance to treatment; knowledge
about the disease; medications; nutrition, motivation for a
change and coping with the disease demands in different
social environments.
Setting
The evaluation was performed between September 2007
and September 2008, in three districts, by MHS’ research
team.
Study population and recruitment
All participants in the all TPE groups in the selected
districts between September 2007 and September 2008
were invited to take part in the study. They were all con-
tacted in advance by telephone, to explain the aims of
the study and to ask for their consent. Those who agreed
were asked to arrive early to the first group meeting to
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We used a validated RTQ questionnaire [13] to measure
resistance to treatment. The RTQ is a four theme, 40 item
questionnaire to measure the core reasons for non-
adherence with treatment: 1: Dissatisfaction with treatment
or team (Therapy); 2: Emotional reasons (Emotions); 3:
specific problems or constraints (Difficulties) and 4: factors
connected to despair and failure (Despair). Scores vary
between 1 (very low resistance) and 5 (very high resis-
tance). In addition, the questionnaire includes items
regarding family status; social support availability; level of
education; age and gender.
Clinical measurement
In order to measure the degree of diabetes control, the
following clinical measurements were included: HbA1C;
diastolic and systolic blood pressure; HDL and LDL
cholesterol; Triglycerides and Body Mass Index (BMI),.
These variables were retrieved from MHS’ computerized
records.
Time periods
Questionnaires were administered at three points: at
recruitment (baseline T1); eight weeks later (at the last
meeting of the intervention) (T2); and six months later
(T3). Clinical measurements were obtained at T1 and
T2, and one year post intervention (T3) (Figure 1).
Data analysis
Study groups
For each core of the RTQ separately, participants were
divided into two groups: those who achieved reduction
at T2 (delta between T2 and T1 <0 - group 1) and those
who failed to achieve reduction (delta between T2 and
T1 = >0 - group 0).
Clinical measurements
Clinical results were collected for T1 and T2 at precise
dates (at recruitment and at the end of the intervention).T1 T2
RTQ+Clinical RTQ+Clinical RTQ
Baseline +8W + 6 
Figure 1 Study time periods.For T3 we documented routinely recorded measure-
ments over the whole year post intervention. For this
time point (T3) we calculated a 12 months average for
each type of variable.
Statistical techniques
For each RTQ core subject separately, we analyzed the
demographic variables between the study groups using
T-test and Chi Square techniques, as required.
Since we had an unbalanced design of repeated mea-
sures, we applied mixed linear models. The dependent
variables were the clinical measurements. The indepen-
dent fixed factors were time of measurement (T1;T2
andT3) and ‘change in resistance’ groups. Subjects were
entered into the model as a random factor (since we had
repeated measures for each subject). For each dependent
variable, we established two models. In the first model,
we included two main effects: time and group in order
to assess whether the two groups differ in baseline mea-
surements. In the second model, we entered an inter-
action between group and time (group*time) in order to
obtain the estimate of the change in the dependent
variable along time in each group. All models were
adjusted according to the univariate analysis (Table 1).
Ethics
The intervention and the evaluation study were both
approved by the local ethics committee.
Results
Diabetes education groups are conducted routinely
throughout the country. During the study period, 26 edu-
cational groups were offered to patients in the selected
regions. Of 210 participants in these groups, 157 (75%)
completed RTQ and had clinical data at T1; 156 (74%) at
T2 and 106 (50%) at T3. Calculations of sample size
revealed sufficient statistical power for 5% and 50% for
Alpha and Beta errors respectively.
No statistically significant differences were found bet-
ween total resistance study groups at baseline (T1); T2
and T3 (Table 2).
Level of education was statistically different between
study groups in the Despair core; mean age in theT3
Clinical (average)
1
Table 1 Personal characteristics by study groups
Variable Despair Emotions
Group 1 Group 0 P Value Group 1 Group 0 P value
Mean age 58.6(9.5) 56.8(9.9) 0.307 55.39(9.6) 60.3(9.2) 0.009
% Females 45.9 58.2 0.169 52.1 50.0 0.817
% <12y educ. 38.6 60.4 0.017 45.1 51.9 0.452
% Married 71.0 86.8 0.037 75.7 80.8 0.506
Mean social support 0.56(0.7) 0.76(0.7) 0.109 0.64(0.6) 0.64(0.7) 0.997
Difficulty Therapy
Group 1 Group 0 P value Group 1 Group 0 P value
Mean age 57.8(9.8) 57.8(9.6) 0.972 56.8(9.9) 59.3(9.3) 0.151
% Females 54.3 47.5 0.440 50.0 53.1 0.736
% <12y educ. 45.5 50.9 0.548 42.1 57.4 0.098
% Married 70.1 87.3 0.023 80.0 74.5 0.474
Mean social support 0.59(0.6) 0.71(0.7) 0.332 0.68(0.7) 0.58(0.6) 0.452
Total resistance
Group 1 Group 0 P value
Mean age 57.5(9.9) 58.5(9.2) 0.588
% Females 51.7 50.0 0.859
% <12y educ. 44.7 55.3 0.279
% Married 76.2 81.6 0.507
Mean social support 0.66(0.6) 0.60(0.6) 0.682
Note: Group 1:achieved reduction at T2 (delta between T2 and T1 <0); group 0: those who failed to achieve reduction (delta between T2 and T1 = >0).
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difficulty cores (Table 1). Study groups were found to be
statistically significant different in all resistance cores at
baseline, meaning group 1 scores were higher than those
of group 0 (Table 3). The results of the linear mixed
models revealed no significant differences between the
study groups at baseline in all clinical measurements
(Table 4). HbA1C was significantly reduced in group 1
between time periods, in the Despair; Difficulty and
Emotion cores while group 0 reduced HbA1C in the
Therapy core and Total Resistance. Diastolic blood pres-
sure was reduced in group 1 in all RTQ cores however,
systolic blood pressure was reduced in group 1 only in
Difficulty and therapy cores. For other clinical measure-
ments no significant changes were observed (Table 4).
Discussion
Our main findings suggest that patients with type 2 dia-
betes who participated in TPE groups and succeeded in
reducing their resistance to treatment achieved better
control of the disease which was sustained for at least
one year of follow up. The reduction obtained was not
only statistically but clinically significant in most cases.
Participants, whose resistance to treatment was signifi-
cantly reduced, were those who began the intervention
with higher levels of resistance. This indicates a regres-
sion to the mean effect, or that the TPE was actuallymore effective for those who have had more difficulties
coping with diabetes. Thus, at this point we may con-
clude that for TPE, it would be more efficient to recruit
the less motivated patients who are coping less well.
Glycosylated Hemoglobin (HbA1C) was the most sig-
nificant clinical measure that was reduced in alignment
with reduction in resistance to treatment. This may indi-
cate that overcoming resistance to treatment is crucial
for better management of diabetes and that the achieved
behavior changes influenced adherence to medication
and dietary guidelines. On the other hand, blood pres-
sure was reduced but not consistently significant among
the resistance cores, and for other clinical measure-
ments: cholesterol; triglycerides and BMI no significant
reduction was observed in both study groups. There is
no clear cut explanation for this, but it is possible that it
is because diabetes was the focus of the TPE and the
agenda emphasizes diabetes management. We analyzed
these variables to allocate an indirect effect.
Resistance to treatment was suggested by previous
studies, as an important factor in the success of the life-
style modifications and in the achievement of desired
outcomes [14,15], mainly in patients with no clear-cut
symptoms, as is the case in most patients diagnosed with
diabetes. The resistance of people with diabetes to treat-
ment and its reasons are poorly understood. The patient
often understands the need for treatment or for lifestyle
Table 2 Clinical measurements at T1 (baseline); T2 and T3
for the two study groups†
Time Group 1 Group 0 P value
N Mean SD N Mean SD
HbA1C
T1 89 7.5 1.8 41 7.1 1.7 0.210
T2 92 7.1 1.4 38 6.9 1.26 0.461
T3 58 7.0 1.2 26 7.1 1.4 0.816
HDL
T1 90 45.5 11.3 40 47.3 13.5 0.447
T2 91 45.0 11.1 39 47.7 12.9 0.265
T3 52 43.6 9.5 26 47.9 12.8 0.138
LDL
T1 90 93.4 29.3 40 96.8 29.0 0.538
T2 91 91.8 32.6 39 92.1 38.2 0.965
T3 52 94.5 32.0 26 92.8 34.7 0.842
TG
T1 90 155.4 70.3 40 162.5 89.5 0.657
T2 91 154.5 70.7 39 176.5 142.5 0.364
T3 53 180.1 97.8 26 190.0 144.8 0.754
BPS
T1 90 132.0 16.9 41 131.0 17.2 0.769
T2 92 130.0 15.2 38 126.6 15.4 0.259
T3 55 129.3 13.6 23 134.1 16.3 0.223
BPD
T1 90 79.0 10.0 41 79.0 9.6 0.992
T2 92 77.6 8.9 38 76.5 9.4 0.517
T3 55 74.7 8.3 23 75.7 10.2 0.675
BMI
T1 88 30.7 5.2 41 29.8 4.9 0.362
T2 89 31.2 6.3 38 30.2 4.8 0.349
T3 58 29.9 4.7 23 29.4 4.5 0.630
SD = Standard Deviation; † Study groups = Total Resistance: delta between T2
and T1 <0 = group 1; delta between T2 and T1 = >0 - group 0
Table 3 Resistance scores at baseline (1very low; 5 very
high) by study groups




Emotional reasons (Emotions) 2.1 1.8 0.007
Specific problems (Difficulty) 2.7 2.4 0.003
Despair and failure (Despair) 2.1 1.7 0.005
Total resistance to treatment
(total resistance)
2.2 2.0 0.254
Note: Group 1:achieved reduction at T2 (delta between T2 and T1 <0); group 0:
those who failed to achieve reduction (delta between T2 and T1 = >0).
Valinsky et al. BMC Endocrine Disorders 2013, 13:61 Page 5 of 7
http://www.biomedcentral.com/1472-6823/13/61change and even intends to make changes to their lifestyle,
but in practice does not take the necessary actions to bring
about these changes. This may be partly explained by
theoretical models, such as the Trans Theoretical Model
(TTM), which emphasizes verbal and behavioral processes
that are associated with four stages of change: thinking
about change, making a decision to change; active change
and maintenance, in addition to patients’ self-efficacy and
belief in their ability to make that change [7-9].
The question is what are the psychological factors
influencing adherence to treatment. Self-efficacy and low
levels of resistance to treatment have been well docu-
mented as having an impact on adherence to treatment
and therefore play a role in the clinical outcome.Moreover, it was suggested that Self-efficacy measurement
could play an important role in diabetes management, in
order to identify where the patient is most likely to adhere
to recommended self-care treatment [13] [16]. We did not
measure self efficacy, because a robust and negative cor-
relation was found between self-efficacy and resistance to
treatment (the higher the resistance to treatment, the less
confident the patient is in his/her ability to manage the
disease) [16]. Although it is possible that measuring self-
efficacy would have added some information regarding
the patients’ state of mind before and after the interven-
tion, we believe that the resistance to treatment was a
good surrogate for self efficacy, and adding more items to
the questionnaire would have reduced our response level.
In our study not all four resistance core components
were equally associated with improvement in the clinical
biochemical outcomes. The reduction in HbA1C was as-
sociated with reduction in feelings of despair, difficulties
and emotions and the reduction in blood pressure was as-
sociated mainly with difficulty and emotions. It is possible
that reducing resistance to treatment at an emotional
level, enhances acceptance of both diabetes and hyper-
tension as a chronic asymptomatic disease, and once the
emotional barrier is overcome the actual changes evolve.
In comparison, weight loss, for example, is associated with
a different type of acceptance which requires a different
set of lifestyle changes.
Regarding the statistical techniques- as mentioned ear-
lier we had an unbalanced design of repeated measure-
ments; we used linear mixed models for each dependent
variable separately as this is the most appropriate ap-
proach for this type of design.
Some limitations of this study should be addressed. This
study is a program review, evaluating changes in outcomes
before and after the intervention with no control group.
The study subjects were not randomly assigned. Only
those who agreed to take part in the evaluated process
participated and were followed up to T3. This probably
leads to selection bias. However, when an intervention is
an integral part of clinical care there is no ethical choice
but to accept those who agreed to participate, both
Table 4 Results of the linear mixed models for resistance to treatment by study groups and time
Total resistance Despair Difficulty Therapy Emotions
HbA1C/P value at baselineα 0.101 0.968 0. 821 0.335 0.912
Estimate† P value Estimate P value Estimate P value Estimate P value Estimate P value
Group1 T2-T1 −0.39 0.001 −0.40 0.011 −0.49 0.002 −0.21 0.371 −0.38 0.005
T3-T1 −0.40 0.001 −0.59 0.001 −0.41 0.022 −0.09 0.700 −0.51 0.003
Group 0 T2-T1 −0.73 0.009 −0.48 0.118 −0.40 0.152 −0.78 0.002 −0.42 0.127
T3-T1 −0.69 0.013 −0.08 0.783 −0.39 0.174 −0.70 0.038 −0. 27 0.352
BPS/P value at baseline 0.999 0.432 0.594 0.616 0.083
Group1 T2-T1 −2.14 0.240 −3.75 0.113 −4.64 0.047 −3.60 0.181 −235 0.241
T3-T1 −4.19 0.031 –1.97 0.460 −5.00 0.067 −6.64 0.026 −2.48 0.305
Group 0 T2-T1 −4.59 0.124 −2.26 0.508 −5.62 0.059 −6.29 0.071 −7.16 0.011
T3-T1 −0.38 0.901 −1.16 0.745 −2.37 0.466 −5.34 1.35 −4.40 0.161
BPD/P value at baseline 0.989 0.091 0.520 0.445 0.665
Total Resistance despair Difficulty Therapy Emotions
Group1 T2-T1 −1.40 0.185 −2.26 0.088 −2.69 0.037 −3.11 0.054 −2.20 0.049
T3-T1 −4.30 <0.001 −5.18 0.001 −5.81 <0.001 −5.16 0.004 −3.85 0.005
Group 0 T2-T1 −2.33 0.193 0.12 0.950 −1.58 0.367 −0.06 0.974 −2.31 0.174
T3-T1 −3.19 0.090 −1.27 0.539 −2.49 0.193 −3.94 0.068 −3.81 0.041
BMI/P value at baseline 0.784 0.046 0.345 0.206 0.508
Group1 T2-T1 0.28 0.416 −0.43 0.315 0.89 0.073 1.20 0.144 0.44 0.262
T3-T1 −0.44 0.215 −0.76 0.112 −0.91 0.113 −0.82 0.279 −0.79 0.099
Group 0 T2-T1 −0.49 0.605 0.54 0.599 −1.16 0.299 −1.50 0.184 −0.65 0.512
T3-T1 −0.76 0.431 −1.04 0.319 −1.39 0.168 1.42 0.224 −0.93 0.368
HDL/P value at baseline 0.415 0.241 0.790 0.769 0.045
Group1 T2-T1 −0.51 0.439 0.59 0.520 −0.50 0.572 −1.90 0.106 −0.58 0.441
T3-T1 −1.13 0.100 0.61 0.560 0.37 0.740 −1.49 0.270 0.24 0.797
Group 0 T2-T1 1.21 0.548 −2.05 0.369 0.82 0.702 1.10 0.631 3.15 0.135
Continue: Total resistance despair Difficulty Therapy Emotions
T3-T1 1.14 0.570 −2.51 0.283 0.57 0.749 0.76 0.739 2.27 0.296
Total resistance despair Difficulty Therapy Emotions
LDL/P value at baseline 0.699 0.235 0.322 0.975 0.267
Group1 T2-T1 −2.58 0.451 −5.35 0.210 −4.34 0.557 −7.47 0.144 −4.25 0.271
T3-T1 −0.50 0.889 1.43 0.766 2.97 0.557 2.26 0.672 −0.15 0.973
Group 0 T2-T1 −3.66 0.539 −6.75 0.298 5.31 0.356 −1.52 0.818 4.04 0.481
T3-T1 −3.17 0.594 −6.35 0.357 4.37 0.479 −3.54 0.592 2.43 0.703
TG/P value at baseline 0.564 0.740 0.095 0.791 0.535
Group1 T2-T1 −3.63 0.602 −1.90 0.840 −17.79 0.068 2.99 0.777 −1.00 0.901
T3-T1 9.90 0.169 23.53 0.042 6.67 0.541 4.85 0.645 14.16 0.154
Group 0 T2-T1 17.29 0.303 12.42 0.462 37.2 0.049 −5.49 0.733 12.68 0.449
T3-T1 18.50 0.271 15.21 0.390 38.4 0.050 8.23 0.609 26.52 0.135
Group 1: achieved reduction at T2 (delta between T2 and T1 <0); group 0: those who failed to achieve reduction (delta between T2 and T1 = >0).
† Estimate = delta between time points αP Value for differences between groups at baseline.
Models for Emotions were adjusted for age; models for difficulty were adjusted for family status; models for despair were adjusted for education and family status.
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adjust in the statistical analysis for the personal variables,
as we did. It is also realistic to expect that in the future,patients with diabetes who choose to participate in TPE
groups, will self-select in a manner similar to that pre-
sented here, making the findings more relevant in the “real
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trol group, we can not assume a causal effect by the inter-
vention on the resistance components and the clinical
measurements. It is therefore recommended that future
research focuses on randomized controlled interventions,
with in-depth examination of the content of diabetes edu-
cation groups, and its impact on behavioral and clinical
outcomes controlling for other important variables such
as duration of diabetes, depression, type of diabetes medi-
cation etc.
Conclusions
The findings from this study support the use of group
education for diabetes self-management. The RTQ ap-
pears to be a useful tool for the measurement of diabetes
related behavioral interventions. Further research is essen-
tial to better understand these associations.
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